Hematology Practice Questions

Q: What is the best treatment for Sickle cell anemia?

Hydroxyurea. **Explanation:** **Hydroxyurea (Option A)** is the mainstay of disease-modifying therapy in Sickle Cell Anemia (SCA) [1]. Its primary mechanism of action is the **induction of Fetal Hemoglobin (HbF)** synthesis. HbF inhibits the polymerization of deoxygenated Hemoglobin S (HbS), thereby preventing the sickling of red blood cells [1]. Clinically, this translates to a significant reduction in the frequency of painful Vaso-occlusive Crises (VOC), Acute Chest Syndrome, and the need for blood transfusions [1]. **Why other options are incorrect:** * **Sulphonamides (Option B):** These are contraindicated or used with caution in many hemolytic anemias (like G6PD deficiency) as they can trigger oxidative stress. They have no role in treating the underlying pathology of SCA. * **Iron Injection (Option C):** Patients with SCA often develop **hemosiderosis** (iron overload) due to chronic hemolysis and repeated transfusions. Administering iron is generally contraindicated unless a concomitant iron deficiency is proven. * **Blood Transfusion (Option D):** While vital for managing acute complications (e.g., stroke, severe anemia, or splenic sequestration), it is not the "best" long-term treatment due to risks of alloimmunization and iron overload [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Hydroxyurea:** Inhibits the enzyme **Ribonucleotide Reductase**, but its benefit in SCA is specifically via increasing γ-globin chain production [1]. * **Monitoring:** Hydroxyurea can cause bone marrow suppression; monitor CBC for neutropenia or thrombocytopenia. * **Cure:** The only definitive **curative** treatment for SCA is Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) [1]. * **Vaccination:** Patients are functionally asplenic; ensure vaccination against encapsulated organisms (*S. pneumoniae, H. influenzae, N. meningitidis*).

Q: What is the blood product of choice for the treatment of hemophilia?

Cryoprecipitate. **Explanation:** The treatment of choice for Hemophilia A (Factor VIII deficiency) among the given options is **Cryoprecipitate**. **1. Why Cryoprecipitate is correct:** Cryoprecipitate is a concentrated subset of plasma proteins obtained by thawing Fresh Frozen Plasma (FFP) at 4°C. It is the "product of choice" among these options because it contains a significantly higher concentration of **Factor VIII**, **von Willebrand Factor (vWF)**, and **Fibrinogen** in a much smaller volume compared to FFP. This allows for effective replacement therapy without the risk of volume overload. **2. Why other options are incorrect:** * **Fresh Frozen Plasma (FFP):** While FFP contains all coagulation factors, the concentration of Factor VIII is low [1]. To achieve therapeutic levels in a hemophilic patient, massive volumes of FFP would be required, leading to **Transfusion-Associated Circulatory Overload (TACO)**. * **Fresh Blood/Plasma:** These contain very dilute amounts of clotting factors and are insufficient for managing acute bleeding episodes in hemophilia. **3. NEET-PG High-Yield Pearls:** * **Gold Standard:** While Cryoprecipitate is the best *blood product* listed, the modern **treatment of choice** is **Recombinant Factor VIII concentrate** [1]. * **Hemophilia B:** Cryoprecipitate does **not** contain Factor IX. Therefore, for Hemophilia B (Christmas Disease), the product of choice is **FFP** (if specific Factor IX concentrates are unavailable). * **Contents of Cryoprecipitate:** Remember the mnemonic **"8, 13, vWF, and Fibrinogen"** (Factors VIII, XIII, von Willebrand Factor, and Fibrinogen). * **Desmopressin (DDAVP):** Used in mild Hemophilia A to release stored Factor VIII from endothelial cells [1]. It is ineffective in Hemophilia B.

Q: Regarding anemia of chronic diseases, all are true except?

Decreased ferritin. **Explanation:** Anemia of Chronic Disease (ACD), also known as Anemia of Inflammation, is driven by the cytokine **Hepcidin** [1]. In chronic inflammatory states (infections, malignancies, autoimmune disorders), IL-6 stimulates the liver to produce Hepcidin. Hepcidin degrades ferroportin, which inhibits iron absorption from the gut and, more importantly, **sequesters iron within macrophages** and hepatocytes [1]. **Why Option B is the correct answer (The "Except"):** In ACD, iron is trapped inside storage cells. **Serum Ferritin**, which reflects total body iron stores and acts as an acute-phase reactant, is **increased or normal**, never decreased. A decreased ferritin is the hallmark of Iron Deficiency Anemia (IDA), not ACD [2]. **Analysis of Incorrect Options:** * **A. Decreased serum iron:** True. Because iron is trapped inside macrophages and not released into the plasma, the circulating (serum) iron level falls [1]. * **C. Decreased TIBC:** True. Total Iron Binding Capacity (TIBC) is a measure of transferrin. In inflammation, the body downregulates transferrin to "starve" pathogens of iron [2]. This helps differentiate ACD (Low TIBC) from IDA (High TIBC). * **D. Increased bone marrow iron:** True. Since iron is sequestered in the reticuloendothelial system, Prussian blue staining of a bone marrow aspirate will show abundant iron in macrophages. **NEET-PG High-Yield Pearls:** 1. **Key Mediator:** Hepcidin (The "Master Regulator" of iron). 2. **Differentiating ACD from IDA:** * **Ferritin:** High/Normal in ACD; Low in IDA [2]. * **TIBC:** Low in ACD; High in IDA [2]. * **Transferrin Saturation:** Low in both. 3. **Soluble Transferrin Receptor (sTfR):** Normal in ACD; Elevated in IDA. This is the most sensitive test to distinguish the two when they coexist.

Q: A 40-year-old male patient is hospitalized with huge splenomegaly, marked sternal tenderness, and a total leukocyte count of 85,000 per cubic millimeter with a large percentage of myelocytes and metamyelocytes. Which one of the following drugs is best indicated for his disease?

Hydroxyurea. ### Explanation **Diagnosis:** The clinical presentation of **huge splenomegaly**, **sternal tenderness** (due to marrow expansion), and a high leukocyte count with a "left shift" (presence of myelocytes and metamyelocytes) is classic for **Chronic Myeloid Leukemia (CML)** in the chronic phase [1]. **Why Hydroxyurea is the Correct Answer:** In the management of CML, **Hydroxyurea** is the preferred agent for **rapid cytoreduction** (lowering the white blood cell count) [1]. It is an antimetabolite that inhibits the enzyme **ribonucleotide reductase**, thereby interfering with DNA synthesis. While Tyrosine Kinase Inhibitors (like Imatinib) are the definitive long-term treatment for CML [1], Hydroxyurea is the drug of choice for immediate control of hyperleukocytosis and symptomatic splenomegaly. **Why Other Options are Incorrect:** * **A. Cyclophosphamide:** An alkylating agent primarily used in lymphomas, leukemias (like CLL), and as an immunosuppressant. It is not a first-line agent for CML. * **B. Chlorambucil:** An alkylating agent used primarily in Chronic Lymphocytic Leukemia (CLL) and some lymphomas. It has no role in the management of CML. * **C. Melphalan:** An alkylating agent used predominantly in the treatment of Multiple Myeloma. **Clinical Pearls for NEET-PG:** * **CML Hallmark:** Presence of the **Philadelphia Chromosome t(9;22)** creating the *BCR-ABL1* fusion gene [1]. * **Sternal Tenderness:** A sign of rapid bone marrow expansion; highly characteristic of CML. * **LAP Score:** Low Leukocyte Alkaline Phosphatase (LAP) score helps differentiate CML from a Leukemoid reaction (where the score is high). * **Definitive Treatment:** Imatinib (TKI) is the gold standard for long-term management, but Hydroxyurea is used for initial "debulking" of the tumor load [1].

Q: Which of the following indicates a poor prognosis in multiple myeloma?

Azotemia. **Explanation:** In Multiple Myeloma (MM), prognosis is determined by tumor burden, host factors, and end-organ damage. **Azotemia (elevated blood urea nitrogen/creatinine)** is a major poor prognostic indicator because it reflects significant renal impairment [1]. Renal failure in MM is often multifactorial (cast nephropathy, hypercalcemia, amyloidosis) and is the second most common cause of death after infection. **Why the other options are incorrect:** * **WBC > 20,000:** While leukocytosis can occur in infections, it is not a standard prognostic marker for MM. In fact, leukopenia (due to marrow infiltration) is more common. * **Hypocalcemia:** **Hypercalcemia** (not hypo) is a hallmark of MM (part of the CRAB criteria) and indicates high bone resorption and poor prognosis. * **Low or normal M component:** A high M-protein spike (>3 g/dL) correlates with a higher tumor burden. However, a very low M-protein in the presence of extensive marrow involvement (Non-secretory myeloma) can sometimes be aggressive, but "low or normal" is generally not a standard poor prognostic marker compared to azotemia. **Clinical Pearls for NEET-PG:** 1. **International Staging System (ISS):** The most important prognostic markers are **Serum Beta-2 Microglobulin** (high = poor) and **Serum Albumin** (low = poor). 2. **Cytogenetics:** Deletion 17p (p53 locus) and t(4;14) are high-risk markers. 3. **CRAB Criteria:** Calcium (elevated), Renal insufficiency, Anemia, Bone lesions [1]. 4. **Renal Failure:** The most common cause is **Bence-Jones proteinuria** leading to "Myeloma Kidney" (Cast Nephropathy) [1].

Q: What is the first test to become positive in patients with Hemochromatosis?

Increased Transferrin Saturation. **Explanation:** In Hereditary Hemochromatosis (HH), the primary defect is a mutation in the **HFE gene**, leading to decreased **Hepcidin** levels. Low hepcidin causes unregulated iron absorption in the duodenum and excessive release of iron from macrophages. **1. Why Transferrin Saturation is the correct answer:** Transferrin saturation (TSAT) is calculated as (Serum Iron / Total Iron Binding Capacity) × 100. Because iron is being absorbed at an abnormally high rate and entering the plasma, the available transferrin molecules become saturated very early in the disease process, often before significant tissue damage or massive storage occurs. It is the **most sensitive screening test** and the first biochemical abnormality to appear. A TSAT >45% is highly suggestive of HH. **2. Why the other options are incorrect:** * **Serum Iron:** While serum iron increases, it is subject to significant daily fluctuations and is not as reliable or early an indicator as the saturation percentage. * **Serum Ferritin:** Ferritin reflects total body iron stores. While it is used to assess the severity of iron overload, it rises **after** transferrin saturation has already increased. It is also an acute-phase reactant, making it less specific. * **Liver Enzymes:** Elevation of ALT/AST occurs only after significant iron deposition leads to structural liver damage (cirrhosis/fibrosis). This is a late manifestation of the disease. **NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** Genetic testing for **C282Y mutation** of the HFE gene. * **Most Accurate Test for Iron Overload:** MRI (T2*) or Liver Biopsy (Perls' Prussian Blue stain). * **Classic Triad (Bronze Diabetes):** Cirrhosis, Diabetes Mellitus, and Skin Hyperpigmentation. * **Treatment of Choice:** Therapeutic Phlebotomy (Target Ferritin: 50–100 ng/mL).

Q: Which of the following conditions is treated with the ABVD chemotherapy regimen?

Hodgkin's disease. **Explanation:** The **ABVD regimen** is the gold standard first-line chemotherapy for **Hodgkin’s Lymphoma (HL)** [1]. It was developed to provide high cure rates while minimizing the long-term risks (such as secondary leukemia and infertility) associated with older regimens like MOPP. The regimen consists of: * **A:** **A**driamycin (Doxorubicin) – An anthracycline (Side effect: Cardiotoxicity). * **B:** **B**leomycin – A cytotoxic antibiotic (Side effect: Pulmonary fibrosis). * **V:** **V**inblastine – A microtubule inhibitor (Side effect: Bone marrow suppression). * **D:** **D**acarbazine – An alkylating agent (Side effect: Highly emetogenic). **Analysis of Incorrect Options:** * **Chronic Lymphocytic Leukemia (CLL):** Typically treated with targeted therapies like Ibrutinib or chemo-immunotherapy regimens such as **FCR** (Fludarabine, Cyclophosphamide, Rituximab) [2]. * **Acute Lymphoblastic Leukemia (ALL):** Requires a complex multi-phase protocol (Induction, Consolidation, Maintenance) involving drugs like Vincristine, Prednisolone, L-Asparaginase, and Daunorubicin. * **Non-Hodgkin’s Lymphoma (NHL):** The standard treatment for the most common subtype (DLBCL) is **R-CHOP** (Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin/Vincristine, and Prednisolone) [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Stanford V** and **BEACOPP** are other regimens used in advanced or refractory Hodgkin’s Disease. * **Brentuximab Vedotin** (anti-CD30 antibody-drug conjugate) is used in relapsed HL. * **Reed-Sternberg cells** (Owl-eye appearance) are the hallmark of Hodgkin’s Disease; they are typically **CD15+ and CD30+** [1]. * Monitoring: Patients on ABVD should undergo **Pulmonary Function Tests (PFTs)** for Bleomycin toxicity and **Echocardiography** for Doxorubicin cardiotoxicity.

Question 1

What is the best treatment for Sickle cell anemia?

Accepted Answer

Hydroxyurea

Answer

Sulphonamide

Answer

Iron Injection

Answer

Blood transfusion

Question 2

What is the blood product of choice for the treatment of hemophilia?

Accepted Answer

Cryoprecipitate

Answer

Fresh blood

Answer

Fresh frozen plasma

Answer

Plasma

Question 3

Regarding anemia of chronic diseases, all are true except?

Accepted Answer

Decreased ferritin

Answer

Decreased serum iron

Answer

Decreased total iron-binding capacity

Answer

Increased bone marrow iron

Question 4

A 39-year-old man has experienced chronic fatigue and weight loss for the past 3 months. There are no remarkable findings on physical examination. Laboratory studies show hemoglobin, 10.0 g/dL; hematocrit, 30.3%; MCV, 91 mm3; platelet count, 240,000/mm3; WBC count, 7550/mm3; serum iron 80 mg/dL; total iron-binding capacity, 145 mg/dL; and serum ferritin, 565 ng/mL. Serum erythropoietin levels are low for the level of Hb and hepcidin levels are elevated. Which of the following is the most likely diagnosis?

Accepted Answer

Anemia of chronic disease

Answer

Aplastic anemia

Answer

Iron deficiency anemia

Answer

Megaloblastic anemia

Question 5

A 40-year-old male patient is hospitalized with huge splenomegaly, marked sternal tenderness, and a total leukocyte count of 85,000 per cubic millimeter with a large percentage of myelocytes and metamyelocytes. Which one of the following drugs is best indicated for his disease?

Accepted Answer

Hydroxyurea

Answer

Cyclophosphamide

Answer

Chlorambucil

Answer

Melphalan

Question 6

Which of the following indicates a poor prognosis in multiple myeloma?

Accepted Answer

Azotemia

Answer

WBC > 20,000

Answer

Hypocalcemia

Answer

Low or normal M component production

Question 7

A 26-year-old woman presents with diffuse abdominal pain and nausea, which began 1 day ago and is now at its maximum intensity. She denies fever but reports constipation and dark urine. She has a history of similar episodes, having undergone appendectomy and cholecystectomy on separate occasions. Physical examination reveals tachycardia, diffuse abdominal tenderness without rebound tenderness, and slightly sluggish bowel sounds. Neurological examination shows decreased sensation to fine and crude touch in both lower extremities up to the knees. Laboratory findings include normal hemoglobin, WBC, and platelet counts. She has mild transaminitis with ALT 123 IU/L, AST 160 IU/L, and ALP 122 IU/L. Urine is red, but a urine dipstick is negative for blood, leukocyte esterase, nitrite, glucose, or protein. Urine porphobilinogen and total porphyrin levels are elevated, while plasma porphyrin levels are normal. What is the most likely explanation for her recurrent symptoms?

Accepted Answer

Acute intermittent porphyria

Answer

Variegate porphyria

Answer

Thalassemia

Answer

Porphyria cutanea tarda

Question 8

What is the first test to become positive in patients with Hemochromatosis?

Accepted Answer

Increased Transferrin Saturation

Answer

Increased Serum Iron

Answer

Increased Serum Ferritin

Answer

Increased Liver Enzymes

Question 9

Which of the following conditions is treated with the ABVD chemotherapy regimen?

Accepted Answer

Hodgkin's disease

Answer

Chronic lymphocytic leukemia

Answer

Acute lymphoblastic leukemia

Answer

Non-Hodgkin's lymphoma

Question 10

Which of the following conditions is not characterized by palpable purpura?

Accepted Answer

Immune thrombocytopenic purpura (ITP)

Answer

Henoch-Schonlein purpura (HSP)

Answer

Scurvy

Answer

Mixed cryoglobulinemia

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?